ExaGrid Named a Finalist in SDC Awards 2019
ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been named a finalist in the Storage, Digitalisation + Cloud (SDC) Awards 2019. The SDC Awards – the new name for Angel Business Communications' IT awards – is firmly focused on recognizing and rewarding success in the products and services that are the foundation for digital transformation. ExaGrid’s EX Series backup storage appliances with data deduplication is nominated for “Backup Storage Innovation of the Year.” Voting to determine the winner in each category is underway now and closes on 15th November 2019 at 17:30 BST. The results will be revealed at an evening gala in London on 27th November 2019.
ExaGrid has gained the nomination due the EX Series’ uniquely scalable architecture and its specialized deduplication process. ExaGrid is best known for its industry-leading approach to backup storage with unique Landing Zone technology, Adaptive Deduplication approach, and cost-effective scale-out architecture. Managing data growth can cause strain on backup storage and ExaGrid set out to develop the best backup target possible. Through its intelligent hyperconverged storage for backup with data deduplication, ExaGrid helps IT organizations solve three of the most pressing issues they face today: how to protect and manage growing data, how to recover data as quickly as possible, and how to do so at a lower cost.
In data backup, organizations retain weekly, monthly and yearly backups in order to account for regulatory audits, legal discovery and other business reasons. It is not uncommon for organizations to retain 20 to 50 copies of their backup data at different historic points in time. As a result, the total backup storage can be 20 to 50 times greater than the initial primary storage copy. The cost of storage for backup becomes prohibitive and difficult to manage. The value that ExaGrid provides stems from its adaptive approach to deduplication, which offers a 20:1 data deduplication ratio. The ExaGrid system can easily scale to accommodate data growth. ExaGrid’s computing software makes the system highly scalable. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour, which is the highest in the industry. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic reducing IT staff maintenance and time.
The traditional inline approach to backup storage only stores deduplicated data. Therefore, both backups and restores are slow as data is deduplicated and rehydrated. As data grows, no additional compute resources are added – so the backup window grows until backups must be abandoned as they are cutting into production hours. Only an expensive, disruptive, forklift upgrade can resolve the longer backup windows. Instead, ExaGrid writes data straight to a disk Landing Zone for the fastest backups, while deduplication happens in parallel. The most recent backup is kept in undeduplicated form in its Landing Zone for the fastest restores and instant VM recovery, since no rehydration is necessary. Long-term retention data is stored deduplicated in the repository, which is a separate section of the appliance.
“ExaGrid’s nomination demonstrates the importance of innovation in the backup storage space and the need for a continued focus on data storage efficiency and cost savings,” said Bill Andrews, CEO and President of ExaGrid. “ExaGrid’s unique scale-out storage architecture provides all compute, network and storage resources for a fixed-length backup window as data grows. This provides essential time savings for strained IT staff. Our approach also eliminates expensive forklift upgrades and planned product obsolescence, which reduces the total cost of ownership for organizations looking to save storage space in their backup environment.”
ExaGrid supports all backup typologies including private cloud, offsite data center, third-party data center, third-party cloud, public cloud, and can operate in a pure hybrid environment.
Lastly, ExaGrid supports a wide variety of backup applications, utilities, and database dumps, such as Veeam, Commvault, Veritas NetBackup, IBM Spectrum Protect, HYCU, Zerto, Acronis and many others. ExaGrid allows multiple approaches within the same environment. An organization can use one backup application for its physical servers, a different backup application or utility for its virtual environment, and also perform direct Microsoft SQL or Oracle RMAN database dumps – all to the same ExaGrid system. This approach allows customers to use the backup application and utilities of their choosing, use best-of-breed backup applications and utilities, and choose the right backup application and utility for each specific use case. If the customer chooses to change their backup application in the future, the ExaGrid system will still work, protecting the initial investment.
About ExaGrid
ExaGrid provides intelligent hyperconverged storage for backup with data deduplication, a unique Landing Zone, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. Its scale-out architecture includes full appliances in a scale-out system and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191030005092/en/
Contact information
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x0248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
